Free · 13,591 studies indexed

lighttherapyresearch.com is a free index of research on photobiomodulation and light therapy, gathered from the world’s journals and trial registries.

Sections
Brain & Neurology

Plasma Brain-Derived Neurotrophic Factor Levels in First-Episode and Recurrent Major Depression and before and after Bright Light Therapy in Treatment-Resistant Depression

However, responders and remitters to BLT had higher post-treatment plasma BDNF concentrations than patients who did not achieve response or remission.

Excerpt from the paper’s abstract. Read the full paper for the details.

AI-generated summary

The authors measured plasma BDNF in first-episode, recurrent-episode and treatment-resistant depression patients and healthy controls, and tracked BDNF in TRD patients during 4 weeks of bright light therapy. All patient groups had lower BDNF than controls, and BLT responders and remitters had higher post-treatment BDNF levels. The authors suggest these BDNF changes may be candidate biomarkers of treatment response.

Who or what was studied
Drug-naive first-episode MDD patients, drug-free recurrent-episode MDD patients, treatment-resistant depression patients (females in the cross-sectional analysis), and healthy controls
Limits stated in the abstract
The abstract does not state the sample size of the longitudinal BLT analysis or the wavelength of the light used, and the findings on biomarkers are presented as candidates rather than established.

Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.

Abstract

Brain-derived neurotrophic factor (BDNF) is implicated in the etiology and treatment response in major depressive disorder (MDD). However, peripheral BDNF concentrations have not been compared across different MDD stages. Bright light therapy (BLT) offers some potential in treatment-resistant depression (TRD), but its effects on BDNF levels are unknown. This study included a cross-sectional analysis of plasma BDNF concentration in females with TRD, unmedicated MDD patients, and healthy controls (HC), and measurements of longitudinal BLT effects on plasma BDNF levels in TRD patients. The present study included 55 drug-naïve, first-episode patients, 25 drug-free recurrent-episode MDD patients, 71 HC participants, and 54 TRD patients. Patients were rated by Hamilton Depression Rating Scale (HAMD)-17 and the Montgomery-Åsberg Depression Rating Scale (MADRS). Patients with TRD received BLT during 4 weeks. The total HAMD-17 and MADRS scores decreased following BLT. All patient groups had lower plasma BDNF than HC, but BDNF levels did not differ between first- and recurrent-episode BDNF patients and TRD patients before or after BLT. However, responders and remitters to BLT had higher post-treatment plasma BDNF concentrations than patients who did not achieve response or remission. The changes in plasma BDNF levels may be candidates for biomarkers of treatment response to BLT in TRD patients.

Abstract reproduced under the CC BY license. Source: PubMed, a service of the National Library of Medicine.

How to read a single study: what to check before relying on this kind of research.

Terms in this paper: Depression, Bright light therapy. Each links to its definition in the glossary.

A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.

Related studies